Seladelpar (MBX-8025)

Primary Biliary Cholangitis (PBC)

Phase 3

Exp Date


Amp Volatility Score


Catalyst Info & Data Links


  • Seladelpar is uniquely suited as a potential treatment for inflammatory liver diseases. In the liver, PPARδ is expressed in multiple cell types including: hepatocytes, cholangiocytes, Kupffer cells and stellate cells. Preclinical and clinical data support its effect on regulating genes involved in bile acids synthesis, inflammation, fibrosis and lipid metabolism, storage and transport.

Updated by JM 

CBAY, CymaBay Therapeutics, Primary Biliary Cholangitis (PBC), Seladelpar (MBX-8025), Liver Disease

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon